Compare Adaptive Biotechnologies Corp (ADPT) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares MSCI India ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.9 (market cap $3.33B), while iShares MSCI India ETF trades at $48.66. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | INDA | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $22.37 | $55.69 |
52-Week Low | $10.24 | $45.42 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
INDA, the iShares MSCI India ETF, trades at $49.88 with a 0.65% daily gain, showing bullish technical momentum with strong moving average signals. The ETF provides exposure to Indian equities, which face mixed sentiment due to AI transition challenges and geopolitical risks, though India's economy grew 7.8% in Q1 2026. Technical indicators show neutral oscillators but overall bullish bias with key support at $49.
The outlook remains cautiously optimistic with India's strong GDP growth offset by sector-specific headwinds. Investment opportunity lies in India's economic expansion and discounted valuation versus S&P 500, while risks include monsoon uncertainties, Middle East tensions affecting inflation, and foreign investor outflows of $26.4 billion in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
